Serum cytokine level fluctuations in chemotherapy-induced myelosuppression.
We have reported that serum granulocyte colony-stimulating factor (G-CSF) and interleukin-6 (IL-6) levels rise in patients with chemotherapy-induced myelosuppression. The aim of the present study was to determine whether other cytokines that function at different hematopoietic stages also fluctuate during chemotherapy-induced myelosuppression and whether the extent of cytokine level fluctuations correlate with myelosuppression severity. Fifteen patients participated in the study. Serum levels of stem cell factor (SCF), interleukin (IL)-1 alpha, IL-6, IL-3, granulocyte-macrophage CSF (GM-CSF) and G-CSF were analyzed before chemotherapy and during the myelosuppressive stage and correlations between cytokine levels and myelosuppression severity were examined. The results showed that both serum G-CSF and IL-6 levels rose in patients with chemotherapy-induced myelosuppression. The prechemotherapy serum G-CSF and IL-6 levels correlated well with their respective elevated levels during the myelosuppressive stage. The myelosuppression severity also correlated well with the extent of serum G-CSF level elevation. The serum IL-6 and G-CSF levels during the myelosuppressive stage correlated significantly. Serum SCF levels did not fluctuate significantly during myelosuppression, and IL-1, IL-3 and GM-CSF were rarely detected in serum even after chemotherapy. In the present study, the roles of IL-1 alpha, SCF, IL-3 and GM-CSF chemotherapy-induced myelosuppression were not clear.
Chen
Y M
YM
Cancer Clinical Research Center, Institute of Biomedical Sciences, Academia Sinica, Taipei, ROC.
Whang-Peng
J
J
Liu
J M
JM
Kuo
B I
BI
Wang
S Y
SY
Tsai
C M
CM
Perng
R P
RP
D000293:Adolescent; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001853:Bone Marrow / Q000187:drug effects*; D002289:Carcinoma, Non-Small-Cell Lung / Q000097:blood / Q000188:drug therapy; D018288:Carcinoma, Small Cell / Q000097:blood / Q000188:drug therapy; D002945:Cisplatin / Q000009:adverse effects; D005047:Etoposide / Q000009:adverse effects; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D016179:Granulocyte Colony-Stimulating Factor / Q000097:blood*; D006801:Humans; D007375:Interleukin-1 / Q000097:blood; D007377:Interleukin-3 / Q000097:blood; D015850:Interleukin-6 / Q000097:blood*; D008175:Lung Neoplasms / Q000097:blood* / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009382:Neoplasms, Unknown Primary / Q000097:blood* / Q000188:drug therapy*; D019089:Stem Cell Factor / Q000097:blood
D000970:Antineoplastic Agents; D007375:Interleukin-1; D007377:Interleukin-3; D015850:Interleukin-6; D019089:Stem Cell Factor; D016179:Granulocyte Colony-Stimulating Factor; D005047:Etoposide; D002945:Cisplatin; D005472:Fluorouracil